Cyclophosphamide Responsive Interstitial Lung Disease in “Overlap Syndrome”

A Clinical Pathology Conference Held by the Division of Rheumatology at the Hospital for Special Surgery

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354(25):2667–76

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Blake DR, Winyard P, Scott DG, Brailsford S, Blann A, Lunec J Endothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteins. Ann Rheum Dis. 1985; 44(3):176–82

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581–6

    Article  PubMed  Google Scholar 

  4. 4.

    Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46(6):1602–13

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikström G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP, Kämpe O, Vanthuyne M, Houssiau FA, Demoulin JB, Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009 Apr; 60(4):1137–44

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114(9):1308–16

    CAS  PubMed  Google Scholar 

  7. 7.

    Diot E, Boissinot E, Asquier E, et al. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998; 114(6):1623–9

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56(6):2005–12

    Article  PubMed  Google Scholar 

  9. 9.

    Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL, Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50(10):3265–74

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54(12):3962–70

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right—heart catheterization. J Rheumatol 2008; 35(3):458–65

    PubMed  Google Scholar 

  12. 12.

    Kirou KA, Mavragani CP, Crow MK, Activation of type I interferon in systemic lupus erythematosus. Expert Rev Clin Immunol 2007; 3(4)579–88

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Massague J, Seoane J, Wotton D, Smad transcription factors. Genes Dev 2005; 19(23):2783–810

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Mavalia C, Scaletti C, Romagnani P, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151(6):1751–8

    CAS  PubMed  Google Scholar 

  15. 15.

    Pandey JP, LeRoy EC, Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 1998; 41(1):10–5

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Pannu J, Trojanowska M, Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004; 16(6):739–45

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Ramirez F, Tanaka S, Bou-Gharios G, Transcriptional regulation of the human alpha2 (I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol 2006; 25(6):365–72

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Sahhar J, Littlejohn G, Conron M, Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Intern Med J 2004; 34(11):626–38

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Sato S, Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11(6):503–7

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Steen VD, Medsger TA, Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66(7):940–4

    Article  PubMed  Google Scholar 

  21. 21.

    Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45(6):694–702

    CAS  Article  Google Scholar 

  22. 22.

    Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25):2655–66

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176(10):1026–34

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Varga J, Abraham D, Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117(3):557–67

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Elizabeth Schulman MD.

Additional information

Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

Each author certifies that his or her institution has approved the reporting of this case, that all investigations were conducted in conformity with ethical principles of research.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schulman, E., Chen, K., Saboeiro, G. et al. Cyclophosphamide Responsive Interstitial Lung Disease in “Overlap Syndrome”. HSS Jrnl 7, 99–105 (2011). https://doi.org/10.1007/s11420-010-9186-8

Download citation

Keywords

  • interstitial lung disease
  • systemic sclerosis
  • overlap syndrome
  • cyclophosphamide